Apeloa Pharmaceutical announces significant share buyback plan

Apeloa Pharmaceutical has unveiled its second share repurchase plan for 2025, committing to an investment of RMB 180 million to RMB 360 million. The company intends to acquire its own shares through centralized bidding on the Shenzhen Stock Exchange, utilizing both its own funds and a specialized repurchase loan from financial institutions. The repurchase price is capped at RMB 23 per share.

The repurchased shares will be allocated for equity incentives or employee stock ownership plans, reflecting the company's commitment to long-term value creation and enhanced investor confidence. Based on the maximum repurchase price and value, Apeloa Pharmaceutical expects to buy back between 7.83 million and 15.65 million shares, representing approximately 0.68% to 1.35% of its total share capital. The repurchase program is scheduled to be completed within 12 months from the board of directors' approval.

As of September 30, 2025, Apeloa Pharmaceutical reported total assets of RMB 12.102 billion and net assets attributable to shareholders of RMB 6.486 billion. The company assures that this repurchase will not negatively impact its operations, financial stability, research and development, debt servicing capabilities, or its listed status. No major shareholders or management personnel have plans to reduce their holdings within the next six months.